Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.

The Journal of antimicrobial chemotherapy - 1 May 1999

Schedletzky H, Wiedemann B, Heisig P

Abstract excerpt

The effect of moxifloxacin on its target enzymes was evaluated by three different approaches: (i) the MICs of moxifloxacin and nine other fluoroquinolones were determined for mutants of Escherichia coli (n = 13) and Staphylococcus aureus (n = 5) carrying different combinations of resistance mutations; (ii) the activity of moxifloxacin on isolated targets was determined as IC50 values for wild-type and mutant type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to DNA Gyrase
Share to DNA Topoisomerase IV

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type I

Share to DNA Topoisomerases, Type II

Share to Fluoroquinolones

Share to Moxifloxacin

Share to Quinolines

Source

Identifiers

PMID: 10382873
DOI: 10.1093/jac/43.suppl_2.31

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.PMID 10382873Read ↗

Activity of and resistance to moxifloxacin in Staphylococcus aureus.Semantic proximity Read ↗

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.Semantic proximity Read ↗

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.Semantic proximity Read ↗

Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.Semantic proximity Read ↗

Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants.Semantic proximity Read ↗

Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.Semantic proximity Read ↗

A double mutation in the gyrA gene is necessary to produce high levels of resistance to moxifloxacin in Campylobacter spp. clinical isolates.Semantic proximity Read ↗

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Semantic proximity Read ↗

Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.Semantic proximity Read ↗

Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.Semantic proximity Read ↗

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.Semantic proximity Read ↗

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.